Clinical trials a vital part of developing new drugs

October 1999
New Orleans CityBusiness (1994 to 2008);10/04/99, Vol. 20 Issue 15, p32
Discusses the role of clinical trials in the development of new drugs. Work by Doctor Edward Hyman on the treatment of Gulf War Syndrome; Process of clinical trials according to cancer researcher Doctor Thomas Cosgriff; Regulation by the Food and Drug Administration.


Related Articles

  • Oversight and Enforcement in Clinical Trials. Wechsler, Jill // Applied Clinical Trials;Sep2000, Vol. 9 Issue 9, p19 

    Reports government inspection and regulation of clinical trial studies in the United States. Selection of clinical sites; Impact of the regulation on the relationship between research oversight and drug development; Recommendations for site inspection; Negligence in reporting clinical trial...

  • New User Fee Program Aims to Spur Drug Development. Wechsler, Jill // Applied Clinical Trials;Aug2002, Vol. 11 Issue 8, p18 

    Reports on the revised user fee program signed into law by U.S. President George W. Bush to encourage clinical trials for drug development. Enhancement of ability of public health agencies to respond to bioterrorist threats; Total approval time for new drug applications; Review of...

  • Business News.  // Applied Clinical Trials;Aug2002, Vol. 11 Issue 8, p56 

    Presents news items on clinical trials for drug development as of August 2002. Budapest-based Hungarian Regulatory Affairs Society's membership in Leefdaal, Belgium-based Pan European Federation of Regulatory Affairs Societies; Entry of Port Jefferson, New York-based Symbio LLC into...

  • CLINICAL TRIALS FOR KIDS.  // Applied Clinical Trials;May2010, Vol. 19 Issue 5, p20 

    The article reports on the drug development for children wherein clinical trials will be conducted for both children and parent particularly in the areas of genetic diseases including cystic fibrosis, influenza and head lice.

  • New FDA step to shorten drug development.  // Medical Marketing & Media;Mar2001, Vol. 36 Issue 3, p32 

    Focuses on the use of single well-controlled trial to shorten drug development time in the U.S.

  • "TMI". Peters, Rita C. // Drug Discovery & Development;Mar2008, Vol. 11 Issue 3, p6 

    The article discusses various reports published within the issue, including one by James Netterwald on the current state of high-content screenings in drug development and another by Neil Canavan on the implications of the lack of attention on clinical trials.

  • Costing drug development.  // Nature Reviews Drug Discovery;Apr2003, Vol. 2 Issue 4, p247 

    Where did that number come from? The eagerly awaited publication of the full study from DiMasi and colleagues invites us to analyse the cost of bringing new drugs to market.

  • Good recruitment Practice = Patient Pull. Bachenheimer, Joan F.; Brescia, Bonnie A. // Pharmaceutical Executive;Jun2003, Vol. 23 Issue 6, p64 

    Discusses Good Recruitment Practice (GRP), a recruitment initiative aimed to increase the needed clinical trial patients in the U.S. Reason for the reluctance of patients to participate in clinical trials; Goals of the GRP initiative; Need to make enrollees feel safe and fully inform to increase...

  • Study Design and the Drug Development Process. Ioannidis, John P. A.; Hozo, Iztok; Djulbegovic, Benjamin // JAMA: Journal of the American Medical Association;5/21/2014, Vol. 311 Issue 19, p2023 

    A response from Benjamin Djulbegovic and colleagues to a letter to the editor on their article about randomized clinical trials (RCTs) and the drug development process in a 2014 issue is presented.


Read the Article

Other Topics